NM_000059.4:c.6495G>A (p.Leu2165=) is a synonymous substitution in BRCA2 exon 11, located outside the clinically important functional domains (PALB2 binding aa 10-40; DNA binding aa 2481-3186).¹ SpliceAI predicts no splicing impact (max delta score = 0.04), consistent with a silent variant that does not alter the mRNA transcript.² BP1_Strong is met: silent substitution outside clinically important functional domains with no splicing predicted (SpliceAI ≤0.1). This provides strong evidence toward a benign interpretation.³ PM2_Supporting is met: the variant is absent from gnomAD v2.1, v4.1, and gnomAD-Canada, supporting rarity in outbred population controls. However, for a synonymous variant with no predicted functional consequence, population absence is more consistent with a rare benign polymorphism than with pathogenicity.⁴ Under ENIGMA BRCA2 v1.2 Table 3 combination rules, BP1_Strong alone does not reach Likely Benign (which requires Strong Benign + Supporting Benign or Moderate Benign + Supporting Benign). With PM2_Supporting pointing in the pathogenic direction, the net classification is Variant of Uncertain Significance (VUS).⁵ This variant has been reported in ClinVar as Likely benign by two clinical laboratories (VariationID 433804, criteria provided, single submitter), consistent with the overall benign direction of evidence.⁶